# US 2020/0383987 A1 · Novel Amide Compound, and Pin1 Inhibitor, Therapeutic Agent for Inflammatory Diseases and Therapeutic Agent for Cancer That Use the Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0383987 A1
- Document ID: US20200383987A1
- Status: Published application
- Kind: A1
- Application number: 16/636,746
- Filed: 2018-08-06
- Published: 2020-12-10
- Earliest claimed: 2017-08-07
- Assignees: Hiroshima University; Tokyo University of Pharmacy & Life Sciences; The University of Tokyo
- Applicants: Hiroshima University; Tokyo University of Pharmacy & Life Sciences; The University of Tokyo
- Inventors: Tomoichiro Asano; Yusuke Nakatsu; Hisanaka Ito; Takayoshi Okabe
- Web page: https://patentgrep.com/patent/US20200383987A1

## CPC

- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- C07C 271/22: to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07C 233/46: with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C 233/51: having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
- C07C 233/63: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 233/87: of a carbon skeleton containing six-membered aromatic rings
- C07C 235/40: having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C 275/28: having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C 275/36: with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
- C07C 275/38: being further substituted by doubly-bound oxygen atoms
- C07D 209/82: Carbazoles; Hydrogenated carbazoles
- C07D 209/88: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D 215/02: having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D 223/24: with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D 265/38: [b, e]-condensed with two six-membered rings
- C07D 295/195: Radicals derived from nitrogen analogues of carboxylic acids
- C07B 2200/07: Optical isomers
- C07C 2601/18: with a ring being at least seven-membered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The purpose of the invention is to develop, as drug-candidate compounds, a group of novel compounds having the activity of inhibiting functions of Pin1. The invention provides: a compound represented by formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic or prophylactic agent for inflammatory diseases, a therapeutic or prophylactic agent for cancer, and a therapeutic or prophylactic agent for adiposity that use said compound/salt.

## Claims

### Claim 1

A compound represented by the Formula (I), or a salt thereof:
wherein m represents an integer of 0 to 2, and n represents an integer of 0 to 1, provided that 0≤m+n≤2;
R1 represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted amino group;
R2 represents an optionally substituted aryl group containing a condensed ring system with three or more rings, a substituted naphthyl group, or a group represented by the following Formula (II), (III), (IV), or (V):
wherein ring A represents an optionally substituted monocyclic heterocyclic group, and rings B and C independently represent an optionally substituted monocyclic or polycyclic aryl or heterocyclic group, and the rings A, B, and C together form a condensed ring system;
wherein rings D and E independently represent an optionally substituted monocyclic or polycyclic aryl or heterocyclic group, and R4 represents a divalent oxy or carbonyl group;
wherein rings D and E independently represent an optionally substituted monocyclic or polycyclic aryl or heterocyclic group;
wherein R4 represents 0 to 7 identical or different substituents attached to the naphthyl group, and Y represents a —NH— group or an alkylene group containing one or two carbon atoms;
R3 represents 0 to 7 identical or different substituents attached to the naphthyl group; and
X represents a single bond, —CH2— group, or —NH— group.

### Claim 2 (depends on 1)

The compound or a salt thereof according to claim 1, wherein R2 is a group represented by the following Formula (II):
wherein ring A represents an optionally substituted monocyclic heterocyclic group, and rings B and C independently represent an optionally substituted monocyclic or polycyclic aryl or heterocyclic group, and the rings A, B, and C together form a condensed ring system.

### Claim 3 (depends on 1)

The compound or a salt thereof according to claim 1, wherein m is 1 and n is 0.

### Claim 4 (depends on 1)

The compound or a salt thereof according to claim 1, wherein R1 represents a hydrogen atom.

### Claim 5 (depends on 1)

The compound or a salt thereof according to claim 1, wherein X represents a single bond.

### Claim 6 (depends on 1)

A Pin1 inhibitor comprising the compound or a salt thereof according to claim 1.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A therapeutic or prophylactic agent for the treatment or prevention of an inflammatory disease associated with fibrosis, comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

### Claim 9 (depends on 8)

The therapeutic or prophylactic agent according to claim 8, further comprising an active ingredient of at least one additional drug for the treatment or prevention of the inflammatory disease associated with fibrosis.

### Claim 10 (depends on 8)

A method of treating or preventing an inflammatory disease associated with fibrosis, comprising administering the therapeutic or prophylactic agent according to claim 8, in combination with at least one additional drug for the treatment or prevention of the inflammatory disease associated with fibrosis.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A method of preparing a medicament for the treatment or prevention of an inflammatory disease associated with fibrosis, comprising combining a pharmaceutically acceptable carrier and a therapeutic or prophylactic amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1.

### Claim 13 (depends on 1)

A method of treating or preventing an inflammatory disease associated with fibrosis, comprising administering the compound or a pharmaceutically acceptable salt thereof according to claim 1 to a patient in need thereof.

### Claim 14 (depends on 1)

A therapeutic or prophylactic agent for the treatment or prevention of cancer, comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

### Claim 15 (depends on 14)

The therapeutic or prophylactic agent according to claim 14, wherein the cancer is colon cancer or prostate cancer.

### Claim 16 (depends on 14)

The therapeutic or prophylactic agent according to claim 14, further comprising an active ingredient of at least one additional drug for the treatment or prevention of cancer.

### Claim 17 (depends on 14)

A method of treating or preventing cancer, comprising administering the therapeutic or prophylactic agent according to claim 14, in combination with at least one additional drug for the treatment or prevention of cancer.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

A method of preparing a medicament for the treatment or prevention of cancer, comprising combining a pharmaceutically acceptable carrier and a therapeutic or prophylactic amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1.

### Claim 20 (depends on 1)

A method of treating or preventing cancer, comprising administering the compound or a pharmaceutically acceptable salt thereof according to claim 1 to a patient in need thereof.

### Claim 21 (depends on 1)

A therapeutic or prophylactic agent for the treatment or prevention of obesity, comprising the compound or a pharmaceutically acceptable salt thereof according to claim 1 as an active ingredient.

### Claim 22 (depends on 21)

The therapeutic or prophylactic agent according to claim 21, further comprising an active ingredient of at least one additional drug for the treatment or prevention of obesity.

### Claim 23 (depends on 21)

A method of treating or preventing obesity, comprising administering the therapeutic or prophylactic agent according to claim 21, in combination with at least one additional drug for the treatment or prevention of obesity.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A method of preparing a medicament for the treatment or prevention of obesity, comprising combining a pharmaceutically acceptable carrier and a therapeutic or prophylactic amount of the compound or a pharmaceutically acceptable salt thereof according to claim 1.

### Claim 26 (depends on 1)

A method of treating or preventing obesity, comprising administering the compound or a pharmaceutically acceptable salt thereof according to claim 1 to a patient in need thereof.
